nach oben

vorheriger Artikel Imaging of a case of benign carotidynia with ul...

nächster Artikel Researcher of the Month

Tipp

Management of dabigatran-induced bleeding: expert statement

Zeitschrift:: Wiener klinische Wochenschrift > Ausgabe 21-22/2013

Autoren:: Dietmar Fries, Alexander Giurea, Manfred Gütl, Walter-Michael Halbmayer, MBA Univ.-Doz. Dr. Sibylle Kozek-Langenecker, Andreas Pachucki, Franz Roithinger, Barbara Steinlechner, Heinrich Thaler, Ansgar Weltermann

Ergänzende Inhalte

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi: 10.1007/s00508-013-0430-3) contains supplementary material, which is available to authorized users.

Summary

The interdisciplinary group of experts has compiled a clinical guidance for manifest dabigatran-induced haemorrhage and envisaged invasive interventions on patients under dabigatran. It recommends an escalation of treatment measures as summarized in a pocket guide (see electronic supplementary material online and insert in the print issue).

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Jetzt informieren

(PDF 66kb)

Fugate JE, Rabinstein AA, McBane RD, Lanzino G. Dabigatran: a primer for neurosurgeons. World Neurosurg. 2012 Jun 19. doi:pii:S1878–8750(12)00639-0. 10.1016/j.wneu.2012.06.019 (Epub ahead of print).

Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American college of chest physicians antithrombotic therapy and prevention of thrombosis panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):7S–47S. PubMedCrossRef

Kozek-Langenecker S, Afshari S, Albaladejo P, Santullano CA, De Robertis E, Filipescu D, Fries D, Görlinger K, Haas T, Imberger G, Jacob M, Lancé M, Llau J, Mallett S, Meier J, Rahe-Meyer N, Samama CM, Smith A, Solomon C, Van der Linden P, Wikkelsø A, Wouters P, Wyffels P. Guidelines on the management of severe perioperative bleeding. Eur J Anaesthesiol. 2013;30(6):270–382. PubMedCrossRef

Weltermann A, Brodmann M, Domanovits H, Eber B, Gottsauner-Wolf M, Halbmayer WM, Hiesmayr JM, Kyrle PA, Längle F, Roithinger FX, Watzke H, Windhager R, Wolf C, Zweiker R. Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. Wien Klin Wochenschr. 2012;124(9–10):340–7. PubMedCrossRef

Cheng JW, Vu H. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. Clin Ther. 2012;34(4):766–87. PubMedCrossRef

Kreutz R. Pharmakologie neuer oraler Antikoagulantien. Grundlage für rationale Entscheidungen. Klinikarzt. 2012;41(S1):10–5.

Spannagl M, Bauersachs E, Debus ES, Gawaz M, Gerlach H, Haas S, Hach-Wunderle V, Lindhoff-Last E, Riess H, Schellong S, Schinzel H, Bode C. Therapie mit Dabigatran—Periinterventionelles Management und Interpretation von Gerinnungstests. Hämostaseologie. 2012;32:294–305. PubMedCrossRef

www.akdae.de; Leitfaden der Arzneimittelkommission der deutschen Ärzteschaft. Orale Antikoagulation bei nicht valvulärem Vorhofflimmern. Empfehlungen zum Einsatz der neuen Antikoagulantien Dabigatran (Pradaxa) und Rivaroxaban (Xarelto). Version 1.0, September 2012.

Samama CM. New anticoagulants: pharmacology and clinical studies. Wien Med Wochenschr. 2011;161(3–4):54–7. PubMedCrossRef

10.

Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral 2 thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292–303. PubMedCrossRef

11.

Sauer H, Wankmüller H, Leschke M. Blutungsmanagement, perioperatives und periprozedurales Bridging: Vorschlag praktischer Strategien für die neuen oralen Antikoagulantien. Klinikarzt. 2012;41:26–32. CrossRef

12.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. PubMedCrossRef

13.

Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document Reviewers, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blömstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbüchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, van Gelder IC, Verheugt FW. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47. PubMedCrossRef

14.

Halbmayer WM, Weigel G, Quehenberger P, et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med. 2012;50(9):1601–5. doi:10.1515/cclm-2011–0888. PubMedCrossRef

15.

Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A, Expert group on coagulation of the external quality assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105(2):371–8. PubMedCrossRef

16.

Omran H, Bauersachs R, Rübenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of 2 oral anticoagulation. Results from the national multicentre BNK Online bridging registry (BORDER). Thromb Haemost. 2012;108(1):65–73. PubMedCrossRef

17.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72. PubMedCrossRef

18.

Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–18. PubMedCrossRef

19.

Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52. PubMedCrossRef

20.

Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements 2 critical care. Transfusion requirements in critical care investigators, canadian critical care trials group. N Engl J Med. 1999;340(6):409–17. PubMedCrossRef

21.

Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Stahel PF, Vincent JL, Spahn DR, Task force for advanced bleeding care in trauma. Management of bleeding following major trauma: an updated European guideline. Crit Care. 2010;14(2):R52. PubMedCrossRef

22.

Fries D, Innerhofer P, Perger P, Gütl M, Hofmann N, Kneifel W, Neuner L, Pernerstorfer T, Pfanner G, Schöchl H, Ziegler B, Kölblinger C, Kozek-Langenecker SA. Gerinnungsmanagement bei traumatisch bedingter Massivblutung. AINS. 2010;45:552–61. PubMed

23.

Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Eng J Med. 2011;365:2038–40. CrossRef

24.

Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012;126(20):2428–32. PubMedCrossRef

25.

Pezborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats (Abstract). Pathophysiol Haemost Thromb. 2010;37:A10–OC251.

26.

van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate—a novel, reversible. oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27. PubMedCrossRef

27.

Eerenberg ES. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation. 2011;124:1573–9. PubMedCrossRef

28.

Baron TH, Kamath PS, McBane RD. Management of anithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368:2113–24. PubMedCrossRef

29.

Kozek-Langenecker S, Sorensen B, Hess J, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Critical Care. 2011;15:R239. PubMedCrossRef

30.

Abdel-Wahab O, Healy B, Dzik W. Effect of fresh frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006;46:1279–85. PubMedCrossRef

31.

Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Hematology Am Soc Hematol Educ Program. 2012;2012:529–35. PubMed

32.

Goodnough LT, Shander A. Special article: current status of pharmacologic therapies. Anesth Analg. 2013;116:15–34. PubMedCrossRef

33.

Regionalanästhesie unter gerinnungshemmender Medikation. Empfehlungen der Arbeitsgruppe perioperative Gerinnung der ÖGARI. http://www.oegari.at/web_files/dateiarchiv/116/Regionalanästhesie%20und%20Gerinnungshemmer%202013.pdf. Last access 24 Sep 2013.

34.

Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau J, Samama M. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999–1015. PubMedCrossRef

35.

Afshari A, Wikkelsø A, Brok J, Møller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev. 2011;(3):CD007871. doi:10.1002/14651858.CD007871.

Titel: Management of dabigatran-induced bleeding: expert statement
Autoren:: Dietmar Fries
Alexander Giurea
Manfred Gütl
Walter-Michael Halbmayer
MBA Univ.-Doz. Dr. Sibylle Kozek-Langenecker
Andreas Pachucki
Franz Roithinger
Barbara Steinlechner
Heinrich Thaler
Ansgar Weltermann
Publikationsdatum: 01.11.2013
DOI: https://doi.org/10.1007/s00508-013-0430-3
Verlag: Springer Vienna
Zeitschrift: Wiener klinische Wochenschrift The Central European Journal of Medicine
Ausgabe 21-22/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Electronic supplementary material

Summary

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Weitere Artikel der Ausgabe 21-22/2013

Researcher of the Month

Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies

Spectrum of pathogens of in-patient children and youths with community acquired pneumonia: a 3 year survey of a community hospital in Vienna, Austria

Imaging of a case of benign carotidynia with ultrasound, MRI and PET–CT

Totally endoscopic congenital heart surgery compared with the traditional heart operation in children

Die Österreichische Apheresegesellschaft